PCML
BIO icon

Pavaki Capital Management LLC’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pavaki Capital Management LLC’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Hold
6,000
– – 0.61% 34
2026
Q1 		$1.67M Hold
6,000
– – 0.71% 31
2025
Q4 		$1.82M Buy
+6,000
New +$1.87M 0.71% 28

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Pavaki Capital Management LLC's BIO Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 6,000 shares worth $1.76M. The position accounts for 0.61% of the portfolio, ranked #34.

Pavaki Capital Management LLC first reported a position in BIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.82M in Q4 2025. 181 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Pavaki Capital Management LLC held 6,000 shares of Bio-Rad Laboratories Class A worth $1.76M as of Q2 2026.
  • Pavaki Capital Management LLC left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
  • Bio-Rad Laboratories Class A made up 0.61% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #34 holding.
  • Pavaki Capital Management LLC first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management LLC's Bio-Rad Laboratories Class A position peaked at $1.82M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.